LSR
0.011
83.3%
IS3
0.001
-75%
ADY
0.006
50%
ADR
0.004
-33.3%
C7A
0.003
50%
TEG
0.002
-33.3%
AON
0.007
40%
L1M
0.043
-28.3%
GTE
0.011
37.5%
ZMM
0.008
-27.3%
MEG
0.023
35.3%
FIN
0.003
-25%
ALM
0.004
33.3%
MKL
0.015
-25%
FCT
0.016
33.3%
RGL
0.003
-25%
FHS
0.004
33.3%
TYX
0.003
-25%
GLH
0.068
33.3%
VRC
0.003
-25%
GTR
0.004
33.3%
WBE
0.003
-25%
GBZ
0.017
30.8%
GLA
0.007
-22.2%
VR1
0.037
27.6%
NHE
0.019
-20.8%
MTM
0.715
25.4%
ADG
0.004
-20%
AAU
0.005
25%
MEM
0.004
-20%
CTN
0.005
25%
SKK
0.004
-20%
SIS
0.005
25%
VEN
0.004
-20%
THR
0.011
22.2%
SRL
0.805
-18.7%
KNB
0.039
21.9%
HIQ
0.014
-17.6%
RPG
0.063
21.2%
EM2
0.005
-16.7%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Tissue Repair (ASX:TRP) has secured TGA approval for TR Pro+™

Tissue Repair (ASX:TRP) has secured a TGA approval for TR Pro+™, the Company’s first advanced wound healing gel product containing the proprietary active ingredient, Glucoprime® (0.1%), derived from yeast.

TR Pro+™ was launched in June 2023 and “represents a new standard in the aftercare of medical and aesthetic procedures.” The TGA listing will enable Tissue Repair to promote its considerable scientific and clinical data more broadly.

Tissue Repair will shortly provide a broader more detailed update presentation from its co-founder and Executive Director Tony Charara in relation to this “significant development” and the Company’s broader strategies in the immediate commercialisation of its proprietary technology as well as the imminent commencement of Phase 3 clinical trials for its advanced wound drug candidate TR987®.

Read the ASX announcement here.

Write to us
  • © 2025 Copyright
  • The Stock Network
  • All rights reserved